▶ SEMAX · SUBTOPIC · SAFETY PROFILE

SEMAX Safety Profile

For Laboratory Research Use Only. This page summarises observed adverse events and regulatory status reported in the peer- reviewed literature. It is not medical advice and does not recommend any human use of SEMAX.

OBSERVED ADVERSE EVENTS IN LITERATURE

The following adverse events have been observed in trials or animal studies of SEMAX. Severity, frequency, and attribution depend on the source publication.

• Mild nasal irritation (intranasal)
• Rare headache
• Limited Western safety data

DRUG INTERACTIONS

The following interactions are reported in or theorised from the published mechanism for SEMAX.

• Other serotonergic/dopaminergic medications (theoretical · unstudied combination)

CONTRAINDICATIONS REPORTED IN LITERATURE

Contraindications recorded for SEMAX in the published record:

• Pregnancy/lactation (unstudied in Western literature)

FDA REGULATORY STATUS

Not FDA-approved. Research-use only in the United States.

WADA REGULATORY STATUS

Not currently listed on the WADA Prohibited List (2026).

SAFETY Q+A FROM LITERATURE

CITED LITERATURE

The safety statements above are drawn from the following peer-reviewed sources. Refer to the originals for adverse- event tables, attribution, and full context.

• Dolotov OV, Karpenko EA, Inozemtseva LS, et al.. Semax, an analog of ACTH(4-10) with cognitive effects, regulates BDNF and trkB expression in the rat hippocampus. Brain Res 2006. PMID 16996037. link
• Dolotov OV, Karpenko EA, Seredenina TS, et al.. Semax, an analogue of adrenocorticotropin (4-10), binds specifically and increases levels of BDNF in rat basal forebrain. J Neurochem 2006. PMID 16635254. link

RELATED PAGES

▶ LAST UPDATED · 2026-05-19